MA-RENAGADE-THERAPEUTICS
27.4.2024 02:10:34 CEST | Business Wire | Press release
ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced its ongoing commitment to exploring the therapeutic opportunity of glycobiology through support for ongoing research at GanNA Bio, and the integration of key individuals of GanNA Bio into the ReNAgade ecosystem. GanNA founders Carolyn Bertozzi, Ph.D., and Richard D. Cummings, Ph.D, will now serve as advisors to ReNAgade.
“ReNAgade will continue to benefit tremendously from GanNA’s promising work in developing extra-hepatic delivery technology that helps expand the breadth and potential of our own RNA medicines,” said Brian Goodman, Co-founder of ReNAgade. “Delivery is foundational to ReNAgade’s mission to overcome the current limitations of RNA medicines. We believe the technology developed within GanNA will help further solidify ReNAgade’s leadership position as we continue advancing our unique, integrated therapeutic platform.”
Formed in 2021 and invested in by ReNAgade, GanNA Bio harnesses novel glycobiology to enable extra-hepatic RNA delivery based on pioneering research licensed from Stanford University, Boston Children’s Hospital, and Beth Israel Deaconess Medical Center. This research was developed in the labs of Carolyn Bertozzi, Ph.D., winner of the 2022 Nobel Prize in Chemistry and Professor of Chemistry in the Stanford School of Humanities and Sciences; Ryan A. Flynn, M.D., Ph.D., Assistant Professor at Boston Children’s Hospital; and Richard D. Cummings, Ph.D., S. Daniel Abraham Professor of Surgery at Beth Israel Deaconess Medical Center, and led by Namita Bisaria, Ph.D, M.B.A., a serial entrepreneur in the RNA therapeutics field. Its platform, based on new advances in glycobiology and synthesis, uses cell-specific glycans to develop next-generation conjugates and unlock the delivery of short and long stranded RNA medicines.
“The combination of GanNA’s innovative glycobiology-based targeting strategy with ReNAgade’s experience in the development of RNA medicines will be a powerful combination for the benefit of patients,” said Dr. Bertozzi. "The progress in glycoRNA science from our seminal publication in the journal Cell is moving fast, and integration with ReNAgade’s pipeline will strengthen our position to develop a broad portfolio of cell-specific delivery systems, leveraging the latest developments in glycobiology in order to expand the array of addressable diseases for RNA medicines. Glycobiology-based RNA medicines represent a new frontier, and it is rewarding to see the possibilities of ReNAgade developing these for clinical use.”
About ReNAgade Therapeutics
ReNAgade exists to unlock the potential for RNA medicines to treat disease anywhere in the body. We combine our novel RNA delivery platforms with a comprehensive RNA platform allowing for an all-RNA system for coding, editing, and gene insertion to develop new medicines.
To accelerate the future of medicine, we bring together a team with deep RNA and delivery expertise to develop paradigm-shifting RNA medicines.
ReNAgade Therapeutics—RNA Without Limits
For more information about the company, its technologies, and its leadership, visit www.renagadetx.com
About GanNA Bio
GanNA was created by Drs. Flynn and Bisaria, and invested by ReNAgade in 2021 following a sponsored research agreement in the lab of Dr. Flynn. The mission is to explore the potential of novel glycobiology therapies following the pioneering work at Stanford University by Drs. Flynn and Bertozzi on glycoRNA. The GanNA Bio Scientific Advisory Board included Drs. Bertozzi, Cummings, Flynn, and ReNAgade CSO, Pete Smith.
University Conflict of Interest Disclosure
Drs. Bertozzi, Cummings and Flynn consult for ReNAgade Therapeutics.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240426251202/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Bentley Systems Announces 2026 Year in Infrastructure Event and YII Awards Honoring the World’s Most Innovative Use of Infrastructure Engineering Software18.3.2026 13:00:00 CET | Press release
Awards build on a two-decade legacy of recognized innovation, setting the benchmark for excellence across the world’s most critical infrastructure assetsCall for nominations now open; submissions will be accepted through May 3, 2026 Bentley Systems, Incorporated (NASDAQ: BSY), the infrastructure engineering software company, today announced the opening of submissions for the Year in Infrastructure event and YII Awards program, which recognizes digital innovation in how infrastructure is designed, built, and operated using Bentley software. Submissions will be accepted through May 3, at 11:59 p.m. EDT. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260318559906/en/ Bentley Systems announced the opening of submissions for the Year in Infrastructure event and YII Awards program, which recognizes digital innovation in how infrastructure is designed, built, and operated using Bentley software. Submissions will be accepted through
Veracode Expands Industry-Leading Fix with AI-Powered SCA Remediation to Combat Software Supply Chain Risk18.3.2026 13:00:00 CET | Press release
New Capability Automates Open-Source Vulnerability Remediation as Software Supply Chain Attacks Surge RSA Conference (booth #435)--Veracode, the global leader in application risk management, today announced Veracode Fix for Software Composition Analysis (SCA), an AI-powered solution to address software supply chain risk. The enhanced automated remediation engine—the next evolution of Veracode’s industry-leading Fix solution—enables organizations to detect and remediate open-source vulnerabilities easily, before code reaches production. Designed to integrate seamlessly into existing developer workflows, it delivers third-party updates and first-party code refactoring without breaking builds or disrupting development. In 2025, software supply chain breaches accounted for 30 percent of external attacks. Meanwhile Veracode’s 2026 State of Software Security (SoSS) Report revealed 82 percent of organizations struggle with escalating security debt, largely due to open-source dependencies. Ver
Armis Appoints Simon Mouyal as Chief Marketing Officer18.3.2026 13:00:00 CET | Press release
Strategic marketing executive to accelerate adoption of Armis Centrix™ in the agentic AI era and extend the company’s category leadership in cyber exposure management and CPS security Armis, the cyber exposure management & security company, today announced the appointment of Simon Mouyal as Chief Marketing Officer. In this role, Mouyal will oversee Armis’ global marketing strategy and execution to accelerate category leadership and demand for Armis Centrix™, the Armis Cyber Exposure Management Platform. During the next phase of Armis’ expansion, he will scale the global marketing organization and help further drive the company’s rapid growth and market penetration. “As we enter our next chapter of hyper-growth, I'm thrilled to have Simon joining our leadership team,” said Yevgeny Dibrov, CEO and Co-Founder of Armis. “Simon will be instrumental in modernizing our global marketing engine and solidifying Armis as the definitive leader in cyber exposure management. He's a category creator
Americhem Appoints Kilian Lamprecht as Vice President of Mergers & Acquisitions to Accelerate Strategic Growth18.3.2026 12:00:00 CET | Press release
Americhem, a global leader in polymer solutions, today announced that Kilian Lamprecht has joined the company as Vice President of Mergers & Acquisitions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260317304976/en/ Kilian Lamprecht, Vice President of Mergers & Acquisitions, Americhem Lamprecht brings extensive experience in corporate development and integration within global industrial and technology organizations. He will work closely with Americhem’s executive leadership team and investment partner PPC to identify and execute strategic acquisitions, partnerships and portfolio investments that expand the company’s capabilities, product portfolio and geographic reach. “Americhem has a long history of disciplined growth and innovation in materials science,” said John Richard, CEO of Americhem. “With the support of PPC, we are expanding our ability to pursue strategic acquisitions that strengthen our technology platform, b
Reply Announces a Partnership With Mistral AI to Develop Sovereign and Enterprise-grade Artificial Intelligence Solutions18.3.2026 09:00:00 CET | Press release
Reply [EXM, STAR: REY] today announced a new partnership agreementwithAI leader Mistral AI aimed at accelerating the adoption of local, customisable, secure and enterprise-grade generative AI solutions at scale. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260318232777/en/ Through this collaboration, Reply and Mistral AI provide a trusted and secure environment on European infrastructures, accelerating the adoption of advanced AI solutions while enabling organizations with stringent regulatory, privacy and data protection requirements to fully leverage generative AI. At the core of the collaboration is a shared vision of frontier AI, designed to enable organizations to adopt AI solutions while ensuring data control, protection of sensitive information, compliance with regulatory requirements and deployment on European infrastructures. By combining Mistral AI’s high-performance AI models with Reply’s expertise in designing
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom